🇺🇸 Sulphadoxine-Pyrimethamine in United States
12 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 12
Most-reported reactions
- Death — 2 reports (16.67%)
- Spina Bifida — 2 reports (16.67%)
- Abasia — 1 report (8.33%)
- Blood Sodium Decreased — 1 report (8.33%)
- Confusional State — 1 report (8.33%)
- Diarrhoea — 1 report (8.33%)
- General Physical Health Deterioration — 1 report (8.33%)
- Haemoglobin Decreased — 1 report (8.33%)
- Hyperkalaemia — 1 report (8.33%)
- Platelet Count Decreased — 1 report (8.33%)
Other Infectious Disease approved in United States
Frequently asked questions
Is Sulphadoxine-Pyrimethamine approved in United States?
Sulphadoxine-Pyrimethamine does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Sulphadoxine-Pyrimethamine in United States?
ORIYOMI OMOTOYOSI AKINYOTU is the originator. The local marketing authorisation holder may differ — check the official source linked above.